Bortezomib in Anti-Cancer Activity: A Potential Drug
<p>26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppressio...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2016-03-08.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_gjct_000007 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Rajagopal Appavu |e author |
| 700 | 1 | 0 | |a Deepa Mohan |e author |
| 245 | 0 | 0 | |a Bortezomib in Anti-Cancer Activity: A Potential Drug |
| 260 | |b Global Journal of Cancer Therapy - Peertechz Publications, |c 2016-03-08. | ||
| 520 | |a <p>26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a target therapy for cancer to promote cell cycle arrest or apoptosis. Bortezomib (Velcade®, PS-341, and Millennium Pharmaceuticals, Inc.) is the first, selective, reversible, and only proteasome inhibitor for the treatment of multiple myeloma have been approved by U.S. Food and Drug Administration (FDA) in 2003. Bortezomib downregulates the interaction of multiple myeloma cells with bone marrow stromal cells, inhibits angiogenesis, and blocks cell cycle progression. Clinically, continuous dosage of bortezomib leads to few side effects.</p> | ||
| 540 | |a Copyright © Rajagopal Appavu et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Mini Review |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/gjct.000007 |z Connect to this object online. |